This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
Blood Cancer Journal Open Access 04 January 2019
-
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
Advances in Therapy Open Access 27 September 2016
-
Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects
Oncology and Therapy Open Access 10 June 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Kenney B, Stack G . Drug-induced thrombocytopenia. Arch Pathol Lab Med 2009; 133: 309–314.
Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106: 3777–3784.
Rasheed W, Bishton M, Johnstone RW, Prince HM . Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther 2008; 8: 413–432.
Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006; 108: 3441–3449.
Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 2008; 14: 4500–4510.
Nishioka C, Ikezoe T, Yang J, Komatsu N, Bandobashi K, Taniguchi A et al. Histone deacetylase inhibitors induce growth arrest and apoptosis of HTLV-1-infected T-cells via blockade of signaling by nuclear factor kappaB. Leuk Res 2008; 32: 287–296.
Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 16639–16647.
Zhang Y, Sun S, Wang Z, Thompson A, Kaluzhny Y, Zimmet J et al. Signaling by the Mpl receptor involves IKK and NF-kappaB. J Cell Biochem 2002; 85: 523–535.
Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173–1186.
Fielder PJ, Gurney AL, Stefanich E, Marian M, Moore MW, Carver-Moore K et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996; 87: 2154–2161.
Corash L, Levin J, Mok Y, Baker G, McDowell J . Measurement of megakaryocyte frequency and ploidy distribution in unfractionated murine bone marrow. Exp Hematol 1989; 17: 278–286.
Matsuoka H, Unami A, Fujimura T, Noto T, Takata Y, Yoshizawa K et al. Mechanisms of HDAC inhibitor-induced thrombocytopenia. Eur J Pharmacol 2007; 571 (2–3): 88–96.
Acknowledgements
This work was supported in part by funding from the Leukemia and Lymphoma Society Translational Research Program to S Lonial. Panobinostat was provided by Novartis. We thank Lauren Moss for assistance with IVIS imaging and platelet counts, Dr Ying Lu for transfection of LBRM-33 with the luciferase vector and the Biostatistics Shared Core Resource at the Winship Cancer Institute for assistance with statistical methods.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S Lonial has received consultant and research support from Novartis. The other authors have no conflict of interest. The writing and interpretation and editorial control of the data and the manuscript were fully under the control of the authors.
Rights and permissions
About this article
Cite this article
Giver, C., Jaye, D., Waller, E. et al. Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes. Leukemia 25, 362–365 (2011). https://doi.org/10.1038/leu.2010.262
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2010.262
This article is cited by
-
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
Blood Cancer Journal (2019)
-
Activity of panobinostat in combination with bortezomib and dexamethasone in advanced, proteasome inhibitor refractory multiple myeloma
memo - Magazine of European Medical Oncology (2017)
-
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
Advances in Therapy (2016)
-
Panobinostat as Pan-deacetylase Inhibitor for the Treatment of Pancreatic Cancer: Recent Progress and Future Prospects
Oncology and Therapy (2016)
-
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients
Leukemia (2014)